Booth No: L832
PharmaEssentia (Taipei Exchange: 6446) develops treatments for myeloproliferative neoplasms, hepatitis and other diseases. Its cGMP biologics facility in Taichung is certified by EMA and TFDA.
− Ropeginterferon alfa-2b for Polycythemia Vera, Chronic Myeloid Leukemia, Essential Thrombocythemia, Myeloid Fibrosis, Hepatitis C (Genotype 2), Hepatitis B
− Oraxol for Breast Cancer
− KX01 for Psoriasis
Exhibitor Press Release
- EU Marketing Authorization for BESREMi® (Ropeginterferon alfa-2b) for rare blood cancer (PV) 2019-05-15
Exhibitors you may be interested in